Clinical trial
A Phase I/II Study of PT-523 in Patients With Refractory Leukemia
NCT00129558 is registered in ClinicalTrials.gov with Spectrum Pharmaceuticals, Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/II Study of PT-523 in Patients With Refractory Leukemia
- Lead sponsor
- Spectrum Pharmaceuticals, Inc
- Phase
- Phase 1/2
- Overall status
- Withdrawn
- Start date
- July 31, 2005
- Completion date
- September 30, 2011
- Enrollment
- 0 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.